

## Ibalizumab

Catalogue No.: abx831129

Ibalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD4 D3 domain, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8, 5.

<b>Target:</b>	CD4 D3 domain
<b>Clonality:</b>	Monoclonal
<b>Reactivity:</b>	Human
<b>Expression:</b>	Recombinant
<b>Tested Applications:</b>	ELISA, WB
<b>Host:</b>	Human
<b>Recommended dilutions:</b>	Optimal dilutions/concentrations should be determined by the end user.
<b>Conjugation:</b>	Unconjugated
<b>Isotype:</b>	IgG4 Kappa
<b>Form:</b>	Liquid
<b>Purity:</b>	> 95%
<b>Purification:</b>	Purified from cell culture supernatants by Protein A/G chromatography.
<b>Storage:</b>	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
<b>Buffer:</b>	0.01 M PBS. pH 7.4.
<b>CAS Number:</b>	680188-33-4
<b>Concentration:</b>	Batch-dependent, typically between 0.5-2.0 mg/ml.

# Datasheet

Version: 2.0.0

Revision date: 04 Dec 2025



**Note:**

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

For Reference Only